The Phase II LUNAR trial demonstrated that adding a PSMA-targeted radiopharmaceutical to stereotactic body radiation therapy (SBRT) significantly slowed progression in oligometastatic prostate cancer compared to SBRT alone. Concurrently, a genomic test was found to predict benefits from adjunct hormone therapy in recurrent prostate cancer patients post-prostatectomy, marking advances in personalized treatment strategies. These findings stem from studies at UCLA Health Jonsson Comprehensive Cancer Center and offer new therapeutic avenues in prostate cancer management.